Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.
Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.
Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.
https://botanixpharma.com/wp-content/uploads/Copy-of-BOT_Website-1.png7361104Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2022-01-20 21:02:572023-03-13 21:16:172022 Edison Open House: Global Healthcare
Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA.
To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology and infection control.
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update.
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs.
Botanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September).
This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions.
Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology.
Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report.
2022 Edison Open House: Global Healthcare
/in Featured, Latest News, News /by Haley ChartresBotanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.
Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.
Click here to register, it’s free.
Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.
Click here to read the report.
AGM Presentation
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA.
To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology and infection control.
Click here to review presentation.
Euroz Hartleys Report | 25 October 2021
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update.
Click here to view the report.
Euroz Hartleys Report | 29 September 2021
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs.
Click here to view the report.
4th International Cannabinoid Derived Pharmaceuticals Summit
/in Featured, Latest News, News /by administratorBotanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September).
This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions.
Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology.
Find out more about the conference HERE
Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report.
Click here to view the report.